+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
a4ß7 Integrin Antagonists Market - Global Forecast 2025-2030- Product Image
a4ß7 Integrin Antagonists Market - Global Forecast 2025-2030- Product Image
Sale

a4ß7 Integrin Antagonists Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 187 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6090385
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The α4β7 Integrin Antagonists Market is experiencing a pivotal shift as innovative immunotherapies drive adoption in gastrointestinal treatment pathways. Rapid developments in drug delivery, personalized medicine, and regulatory strategies are defining the competitive landscape, making this market essential for strategic investment and proactive leadership.

Market Snapshot: α4β7 Integrin Antagonists

The α4β7 Integrin Antagonists Market grew from USD 244.15 million in 2024 to USD 269.98 million in 2025. With a strong CAGR of 10.84%, this market is projected to reach USD 452.81 million by 2030. This trajectory reflects the increasing uptake of targeted immunotherapies for challenging gastrointestinal conditions, with both established pharmaceutical firms and emerging biotech companies seeking to expand portfolios in this high-value segment.

Scope & Segmentation

  • Drug Types: Includes agents such as Natalizumab, Vedolizumab, and next-generation integrin antagonists optimized for selectivity and safety.
  • Mode of Administration: Options feature traditional intravenous infusions and subcutaneous formulations that enable outpatient and home care settings.
  • Mechanisms of Action: Encompass non-selective integrin blockade and selective β7 integrin targeting, each with distinct profiles for immune modulation.
  • Therapeutic Applications: Focused on Crohn’s Disease, Ulcerative Colitis, and Inflammatory Bowel Disease, with tailored approaches to meet various clinical needs.
  • Regional Coverage: Americas (including United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (with key countries such as UK, Germany, France, UAE, and South Africa), and Asia-Pacific (covering China, India, Japan, Australia, and additional major markets).
  • Company Profiles: Analysis covers leading organizations such as Biogen, C4X Discovery Ltd., Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche AG, Gilead Sciences, Inc., and others active in development, manufacturing, and collaboration.

Key Takeaways

  • α4β7 integrin antagonists are central to new standards in gastrointestinal immunotherapy, due to their targeted mechanism and favorable safety outcomes.
  • The emergence of subcutaneous drug formulations aligns with decentralized care and patient preference, further accelerating adoption alongside traditional intravenous approaches.
  • Expansion of next-generation molecules and advancing biomarker strategies are refining patient selection and trial design, supporting more personalized, value-driven therapies.
  • Collaborative partnerships are increasingly critical, enabling knowledge transfer, regulatory acceleration, and optimizing manufacturing scalability for global reach.
  • Pricing models and payer negotiations are undergoing realignment as market participants address increased input costs, particularly in regions impacted by evolving trade policies.

Tariff Impact: United States 2025 Changes

Tariff adjustments introduced by the United States in 2025 have added complexity to the global α4β7 integrin antagonists supply chain. These changes have led manufacturers to adapt sourcing strategies, invest in regional production capacity, and revisit commercial agreements with suppliers and distributors. Healthcare payers are responding with innovative reimbursement models and localized partnerships, all aiming to maintain affordability and steady access in the face of cost pressures. Industry stakeholders attentive to regulatory harmonization and supply chain agility are best positioned to minimize disruption and sustain their market advantage.

Market Methodology & Data Sources

This report integrates multi-method research, blending expert interviews, clinical and industry data, regulatory filings, and peer-reviewed literature. Quantitative and qualitative analyses inform market projections and stakeholder priorities. Stringent validation, including peer review and conflict resolution, ensures reliability and actionable insights for strategic decisions.

Why This Report Matters

  • Enables executive teams and product strategists to evaluate opportunities driven by breakthroughs in selective targeting, delivery innovation, and region-specific dynamics.
  • Provides a structured framework for understanding evolving payer models, regulatory shifts, and collaboration strategies, guiding investment and market access initiatives.
  • Delivers an integrated perspective that supports evidence-based planning and competitive differentiation within the gastrointestinal immunotherapy sector.

Conclusion

The α4β7 Integrin Antagonists Market is set to shape future therapeutic standards for chronic gastrointestinal diseases. Organizations that optimize innovation, supply chain flexibility, and stakeholder engagement will drive sustained market success and clinical impact.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Real-world evidence supporting the long-term safety and efficacy of subcutaneous vedolizumab in moderate to severe ulcerative colitis patients
5.2. Emerging competitive pressure from novel oral small-molecule a4ß7 integrin inhibitors in development pipelines
5.3. Market access challenges driven by evolving value-based pricing and reimbursement policies for integrin antagonist therapies
5.4. Head-to-head clinical trials evaluating etrolizumab versus anti-TNF agents in anti-TNF refractory Crohn’s disease populations
5.5. Advancements in biomarker-driven patient stratification to optimize a4ß7 antagonist treatment outcomes in IBD
5.6. Growing interest in combination regimens pairing a4ß7 inhibitors with JAK inhibitors to enhance remission rates in Crohn’s disease
5.7. Impact of biosimilar vedolizumab introductions on price competitiveness and prescribing dynamics in developed markets
5.8. Pediatric authorization trends for a4ß7 integrin blockers expanding treatment options for adolescent ulcerative colitis patients
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. a4ß7 Integrin Antagonists Market, by Drug Type
8.1. Introduction
8.2. Natalizumab
8.3. Vedolizumab
9. a4ß7 Integrin Antagonists Market, by Mode of Administration
9.1. Introduction
9.2. Intravenous
9.3. Subcutaneous
10. a4ß7 Integrin Antagonists Market, by Mechanism of Action
10.1. Introduction
10.2. Non-Selective Integrin Blockade
10.3. Selective ß7 Integrin Blockade
11. a4ß7 Integrin Antagonists Market, by Therapeutic Application
11.1. Introduction
11.2. Crohn's Disease
11.3. Inflammatory Bowel Disease
11.4. Ulcerative Colitis
12. Americas a4ß7 Integrin Antagonists Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa a4ß7 Integrin Antagonists Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific a4ß7 Integrin Antagonists Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Biogen
15.3.2. C4X Discovery Ltd.
15.3.3. EA Pharma Co., Ltd.
15.3.4. Elli Lilly and Company
15.3.5. Ensho Therapeutics, Inc.
15.3.6. F. Hoffmann-La Roche AG
15.3.7. Gilead Sciences, Inc.
15.3.8. Merck
15.3.9. Polypharma Group BV
15.3.10. Protagonist Therapeutics Inc.
15.3.11. Real-Gene Labs
15.3.12. RedHill Biopharma Ltd.
15.3.13. Takeda Pharmaceutical Company Limited
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. ?4?7 INTEGRIN ANTAGONISTS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ?4?7 INTEGRIN ANTAGONISTS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. ?4?7 INTEGRIN ANTAGONISTS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. ?4?7 INTEGRIN ANTAGONISTS MARKET: RESEARCHAI
FIGURE 24. ?4?7 INTEGRIN ANTAGONISTS MARKET: RESEARCHSTATISTICS
FIGURE 25. ?4?7 INTEGRIN ANTAGONISTS MARKET: RESEARCHCONTACTS
FIGURE 26. ?4?7 INTEGRIN ANTAGONISTS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. ?4?7 INTEGRIN ANTAGONISTS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY NATALIZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY NATALIZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY VEDOLIZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY VEDOLIZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY NON-SELECTIVE INTEGRIN BLOCKADE, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY NON-SELECTIVE INTEGRIN BLOCKADE, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY SELECTIVE ?7 INTEGRIN BLOCKADE, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY SELECTIVE ?7 INTEGRIN BLOCKADE, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY CROHN'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY CROHN'S DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. AMERICAS ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 36. AMERICAS ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 37. AMERICAS ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 38. AMERICAS ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 39. AMERICAS ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 40. AMERICAS ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 41. AMERICAS ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 42. AMERICAS ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 43. AMERICAS ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 44. AMERICAS ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 45. UNITED STATES ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 46. UNITED STATES ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 47. UNITED STATES ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 48. UNITED STATES ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 49. UNITED STATES ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 50. UNITED STATES ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 51. UNITED STATES ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 52. UNITED STATES ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 53. UNITED STATES ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 54. UNITED STATES ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 55. CANADA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 56. CANADA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 57. CANADA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 58. CANADA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 59. CANADA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 60. CANADA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 61. CANADA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 62. CANADA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 63. MEXICO ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 64. MEXICO ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 65. MEXICO ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 66. MEXICO ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 67. MEXICO ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 68. MEXICO ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 69. MEXICO ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 70. MEXICO ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 71. BRAZIL ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 72. BRAZIL ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 73. BRAZIL ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 74. BRAZIL ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 75. BRAZIL ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 76. BRAZIL ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 77. BRAZIL ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 78. BRAZIL ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 79. ARGENTINA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 80. ARGENTINA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 81. ARGENTINA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 82. ARGENTINA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 83. ARGENTINA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 84. ARGENTINA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 85. ARGENTINA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 86. ARGENTINA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 87. EUROPE, MIDDLE EAST & AFRICA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 88. EUROPE, MIDDLE EAST & AFRICA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 89. EUROPE, MIDDLE EAST & AFRICA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 90. EUROPE, MIDDLE EAST & AFRICA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 91. EUROPE, MIDDLE EAST & AFRICA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 92. EUROPE, MIDDLE EAST & AFRICA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 93. EUROPE, MIDDLE EAST & AFRICA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 94. EUROPE, MIDDLE EAST & AFRICA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 95. EUROPE, MIDDLE EAST & AFRICA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 96. EUROPE, MIDDLE EAST & AFRICA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 97. UNITED KINGDOM ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 98. UNITED KINGDOM ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 99. UNITED KINGDOM ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 100. UNITED KINGDOM ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 101. UNITED KINGDOM ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 102. UNITED KINGDOM ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 103. UNITED KINGDOM ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 104. UNITED KINGDOM ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 105. GERMANY ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 106. GERMANY ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 107. GERMANY ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 108. GERMANY ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 109. GERMANY ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 110. GERMANY ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 111. GERMANY ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 112. GERMANY ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 113. FRANCE ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 114. FRANCE ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 115. FRANCE ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 116. FRANCE ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 117. FRANCE ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 118. FRANCE ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 119. FRANCE ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 120. FRANCE ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 121. RUSSIA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 122. RUSSIA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 123. RUSSIA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 124. RUSSIA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 125. RUSSIA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 126. RUSSIA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 127. RUSSIA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 128. RUSSIA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 129. ITALY ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 130. ITALY ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 131. ITALY ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 132. ITALY ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 133. ITALY ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 134. ITALY ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 135. ITALY ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 136. ITALY ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 137. SPAIN ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 138. SPAIN ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 139. SPAIN ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 140. SPAIN ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 141. SPAIN ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 142. SPAIN ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 143. SPAIN ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 144. SPAIN ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 145. UNITED ARAB EMIRATES ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 146. UNITED ARAB EMIRATES ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 147. UNITED ARAB EMIRATES ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 148. UNITED ARAB EMIRATES ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 149. UNITED ARAB EMIRATES ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 150. UNITED ARAB EMIRATES ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 151. UNITED ARAB EMIRATES ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 152. UNITED ARAB EMIRATES ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 153. SAUDI ARABIA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 154. SAUDI ARABIA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 155. SAUDI ARABIA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 156. SAUDI ARABIA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 157. SAUDI ARABIA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 158. SAUDI ARABIA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 159. SAUDI ARABIA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 160. SAUDI ARABIA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 161. SOUTH AFRICA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 162. SOUTH AFRICA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 163. SOUTH AFRICA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 164. SOUTH AFRICA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 165. SOUTH AFRICA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 166. SOUTH AFRICA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 167. SOUTH AFRICA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 168. SOUTH AFRICA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 169. DENMARK ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 170. DENMARK ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 171. DENMARK ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 172. DENMARK ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 173. DENMARK ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 174. DENMARK ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 175. DENMARK ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 176. DENMARK ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 177. NETHERLANDS ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 178. NETHERLANDS ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 179. NETHERLANDS ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 180. NETHERLANDS ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 181. NETHERLANDS ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 182. NETHERLANDS ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 183. NETHERLANDS ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 184. NETHERLANDS ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 185. QATAR ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 186. QATAR ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 187. QATAR ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 188. QATAR ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 189. QATAR ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 190. QATAR ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 191. QATAR ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 192. QATAR ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 193. FINLAND ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 194. FINLAND ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 195. FINLAND ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 196. FINLAND ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 197. FINLAND ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 198. FINLAND ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 199. FINLAND ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 200. FINLAND ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 201. SWEDEN ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 202. SWEDEN ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 203. SWEDEN ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 204. SWEDEN ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 205. SWEDEN ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 206. SWEDEN ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 207. SWEDEN ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 208. SWEDEN ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 209. NIGERIA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 210. NIGERIA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 211. NIGERIA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 212. NIGERIA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 213. NIGERIA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 214. NIGERIA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 215. NIGERIA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 216. NIGERIA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 217. EGYPT ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 218. EGYPT ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 219. EGYPT ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 220. EGYPT ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 221. EGYPT ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 222. EGYPT ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 223. EGYPT ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 224. EGYPT ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 225. TURKEY ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 226. TURKEY ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 227. TURKEY ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 228. TURKEY ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 229. TURKEY ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 230. TURKEY ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 231. TURKEY ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 232. TURKEY ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 233. ISRAEL ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 234. ISRAEL ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 235. ISRAEL ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 236. ISRAEL ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 237. ISRAEL ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 238. ISRAEL ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 239. ISRAEL ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 240. ISRAEL ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 241. NORWAY ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 242. NORWAY ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 243. NORWAY ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 244. NORWAY ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 245. NORWAY ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 246. NORWAY ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 247. NORWAY ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 248. NORWAY ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 249. POLAND ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 250. POLAND ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 251. POLAND ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 252. POLAND ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 253. POLAND ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 254. POLAND ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 255. POLAND ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 256. POLAND ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 257. SWITZERLAND ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 258. SWITZERLAND ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 259. SWITZERLAND ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 260. SWITZERLAND ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 261. SWITZERLAND ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 262. SWITZERLAND ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 263. SWITZERLAND ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 264. SWITZERLAND ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 265. ASIA-PACIFIC ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 266. ASIA-PACIFIC ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 267. ASIA-PACIFIC ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 268. ASIA-PACIFIC ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 269. ASIA-PACIFIC ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 270. ASIA-PACIFIC ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 271. ASIA-PACIFIC ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 272. ASIA-PACIFIC ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 273. ASIA-PACIFIC ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 274. ASIA-PACIFIC ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 275. CHINA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 276. CHINA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 277. CHINA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 278. CHINA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 279. CHINA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 280. CHINA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 281. CHINA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 282. CHINA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 283. INDIA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 284. INDIA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 285. INDIA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 286. INDIA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 287. INDIA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 288. INDIA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 289. INDIA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 290. INDIA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 291. JAPAN ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 292. JAPAN ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 293. JAPAN ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 294. JAPAN ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 295. JAPAN ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 296. JAPAN ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 297. JAPAN ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 298. JAPAN ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 299. AUSTRALIA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 300. AUSTRALIA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 301. AUSTRALIA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 302. AUSTRALIA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 303. AUSTRALIA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 304. AUSTRALIA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 305. AUSTRALIA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 306. AUSTRALIA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 307. SOUTH KOREA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 308. SOUTH KOREA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 309. SOUTH KOREA ?4?7 INTEGRIN ANTAGONISTS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this α4β7 Integrin Antagonists market report include:
  • Biogen
  • C4X Discovery Ltd.
  • EA Pharma Co., Ltd.
  • Elli Lilly and Company
  • Ensho Therapeutics, Inc.
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • Merck
  • Polypharma Group BV
  • Protagonist Therapeutics Inc.
  • Real-Gene Labs
  • RedHill Biopharma Ltd.
  • Takeda Pharmaceutical Company Limited

Table Information

Report AttributeDetails
No. of Pages187
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 269.98 Million
Forecasted Market Value ( USD ) by 2030 $ 452.81 Million
Compound Annual Growth Rate10.8%
Regions CoveredGlobal
No. of Companies Mentioned14

Related Topics

Related Reports

Alpha4beta7 Integrin Antagonists - Pipeline Insight, 2025 - Product Image

Alpha4beta7 Integrin Antagonists - Pipeline Insight, 2025

  • Drug Pipelines
  • 60 Pages
  • Global
From
Alpha V Beta 3 Integrin Antagonist - Pipeline Insight, 2025 - Product Image

Alpha V Beta 3 Integrin Antagonist - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Dementia Drugs Market - Global Forecast 2025-2030 - Product Image

Dementia Drugs Market - Global Forecast 2025-2030

  • Report
  • 196 Pages
  • Global
From
Insomnia Drugs Market - Global Forecast 2025-2030 - Product Image

Insomnia Drugs Market - Global Forecast 2025-2030

  • Report
  • 189 Pages
  • Global
From
Neuroprotection Therapeutics - Global Strategic Business Report - Product Image

Neuroprotection Therapeutics - Global Strategic Business Report

  • Report
  • 194 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.